Pharmacogenetic guidelines and decision support tools for depression treatment: application to late-life

References

• 1 Fiske A, Wetherell JL, Gatz M. Depression in older adults. Annu. Rev. Clin. Psychol. 5, 363–389 (2009).
  MedlineGoogle Scholar
• 2 Centers for Disease Control and Prevention. Current depression among adults – United States, 2006 and 2008. Morb. Mortal. Wkly Rep. 59, 1229–1235 (2010).
  MedlineGoogle Scholar
• 3 Pratt LA, Brody DJ, Gu Q. Antidepressant use in persons aged 12 and over: United States, 2005-2008. NCHS Data Brief 76, 1–8 (2011).
  Google Scholar
• 4 Blazer DG. Depression in late life: review and commentary. J. Gerontol. A Biol. Sci. Med. Sci. 58, M249–M265 (2003).
  MedlineGoogle Scholar
• 5 Wang PS, Schneeweiss S, Brookhart MA et al. Suboptimal antidepressant use in the elderly. J. Clin. Psychopharmacol. 25, 118–126 (2005).
  Medline CASGoogle Scholar
• 6 Hanlon JT, Wang X, Castle NG et al. Potential underuse, overuse, and inappropriate use of antidepressants in older veteran nursing home residents. J. Am. Geriatr. Soc. 59, 1412–1420 (2011).
  MedlineGoogle Scholar
• 7 Barry LC, Abou JJ, Simen AA, Gill TM. Under-treatment of depression in older persons. J. Affect Disord. 136, 789–796 (2012).
  MedlineGoogle Scholar
• 8 Kok RM, Nolen WA, Heeren TJ. Efficacy of treatment in older depressed patients: a systematic review and meta-analysis of double-blind randomized controlled trials with antidepressants. J. Affect. Disord. 141, 103–115 (2012).
  Medline CASGoogle Scholar
• 9 Alexopoulos GS, Schultz SK, Lebowitz BD. Late-life depression: a model for medical classification. Biol. Psychiatry 58, 283–289 (2005).
  MedlineGoogle Scholar
• 10 Kok RM, Reynolds CF. Management of depression in older adults. JAMA 317, 2114 (2017).
  Medline CASGoogle Scholar
• 11 Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin. Drug Saf. 13, 57–65 (2014).
  MedlineGoogle Scholar
• 12 Elliott LS, Henderson JC, Neradilek MB, Moyer NA, Ashcraft KC, Thirumaran RK. Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: a prospective pilot randomized controlled trial. PLoS ONE 12, e0170905 (2017).
  MedlineGoogle Scholar
• 13 Safran DG, Neuman P, Schoen C et al. Prescription drug coverage and seniors: findings from a 2003 national survey. Health Aff. (Millwood) Suppl. Web. W5-152–W5-166 (2005).
  Google Scholar
• 14 Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N. Engl. J. Med. 365, 2002–2012 (2011).
  Medline CASGoogle Scholar
• 15 Gentile G, Cipolla F, Capi M, Simmaco M, Lionetto L, Borro M. Precise medical decision making in geriatric anti-depressant therapy. Expert Rev. Precis. Med. Drug Dev. 1, 387–396 (2016).
  Google Scholar
• 16 Meltzer CC, Price JC, Mathis CA et al. Serotonin 1A receptor binding and treatment response in late-life depression. Neuropsychopharmacology 29, 2258–2265 (2004).
  Medline CASGoogle Scholar
• 17 Pollock BG. The pharmacokinetic imperative in late-life depression. J. Clin. Psychopharmacol. 25, S19–S23 (2005).
  MedlineGoogle Scholar
• 18 Abbott R, Chang DD, Eyre HA, Bousman CA, Merrill DA, Lavretsky H. Pharmacogenetic decision support tools: a new paradigm for late-life depression? Am. J. Geriatr. Psychiatry 26, 125–133 (2018).
  MedlineGoogle Scholar
• 19 Bousman CA, Hopwood M. Commercial pharmacogenetic-based decision-support tools in psychiatry. Lancet Psychiatry 3, 585–590 (2016).
  MedlineGoogle Scholar
• 20 Eyre HA, Yang H, Leaver AM et al. Altered resting-state functional connectivity in late-life depression: a cross-sectional study. J. Affect Disord. 189, 126–133 (2016b).
  MedlineGoogle Scholar
• 21 Eyre HA, Siddarth P, van Dyk K et al. Neural correlates of apathy in late-life depression: a pilot [18F]FDDNP positron emission tomography study. Psychogeriatrics 17, 186–193 (2017).
  MedlineGoogle Scholar
• 22 Hopkins RO, Beck CJ, Burnett DL, Weaver LK, Victoroff J, Bigler ED. Prevalence of white matter hyperintensities in a young healthy population. J. Neuroimaging 16, 243–251 (2006).
  MedlineGoogle Scholar
• 23 Alexopoulos GS. Frontostriatal and limbic dysfunction in late-life depression. Am. J. Geriatr. Psychiatry 10, 687–695 (2002).
  MedlineGoogle Scholar
• 24 Sheline YI, Pieper CF, Barch DM et al. Support for the vascular depression hypothesis in late-life depression: results of a 2-site, prospective, antidepressant treatment trial. Arch. Gen. Psychiatry 67, 277–285 (2010).
  MedlineGoogle Scholar
• 25 Lavretsky H. Intervention research in late-life depression: challenges and opportunities. Am. J. Geriatr. Psychiatry 24, 6–10 (2016).
  MedlineGoogle Scholar
• 26 Pimontel MA, Rindskopf D, Rutherford BR, Brown PJ, Roose SP, Sneed JR. A meta-analysis of executive dysfunction and antidepressant treatment response in late-life depression. Am. J. Geriatr. Psychiatry 24, 31–41 (2016).
  MedlineGoogle Scholar
• 27 Reeve E, Trenaman SC, Rockwood K, Hilmer SN. Pharmacokinetic and pharmacodynamic alterations in older people with dementia. Expert Opin. Drug Metab. Toxicol. 13, 651–668 (2017).
  MedlineGoogle Scholar
• 28 van Tongeren SP, Slaets JPJ, Harmsen HJM, Welling GW. Fecal microbiota composition and frailty. Appl. Environ. Microbiol. 71, 6438–6442 (2005).
  Medline CASGoogle Scholar
• 29 Claesson MJ, Cusack S, O'Sullivan O et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc. Natl Acad. Sci. USA 108(Suppl.), 4586–4591 (2011).
  Medline CASGoogle Scholar
• 30 Farrall AJ, Wardlaw JM. Blood–brain barrier: ageing and microvascular disease – systematic review and meta-analysis. Neurobiol Aging 30, 337–352 (2009).
  Medline CASGoogle Scholar
• 31 Toornvliet R, van Berckel BNM, Luurtsema G et al. Effect of age on functional P-glycoprotein in the blood–brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. Clin. Pharmacol. Ther. 79, 540–548 (2006).
  Medline CASGoogle Scholar
• 32 Uhr M, Grauer MT, Holsboer F. Differential enhancement of antidepressant penetration into the brain in mice with ABCB1ab (MDR1ab) P-glycoprotein gene disruption. Biol. Psychiatry 54, 840–846 (2003).
  Medline CASGoogle Scholar
• 33 Uhr M, Tontsch A, Namendorf C et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 57, 203–209 (2008).
  Medline CASGoogle Scholar
• 34 Breitenstein B, Scheuer S, Brückl TM et al. Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: results from a randomized clinical study. J. Psychiatr. Res. 73, 86–95 (2016).
  MedlineGoogle Scholar
• 35 Anantharaju A, Feller A, Chedid A. Aging liver: a review. Gerontology 48, 343–353 (2002).
  Medline CASGoogle Scholar
• 36 Sotaniemi EA, Lumme P, Arvela P, Rautio A. Age and CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in man. Therapie 51, 363–366 (1996).
  Medline CASGoogle Scholar
• 37 DeVane CL, Pollock BG. Pharmacokinetic considerations of antidepressant use in the elderly. J. Clin. Psychiatry 60(Suppl. 2), 38–44 (1999).
  Medline CASGoogle Scholar
• 38 Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp. Gerontol. 38, 843–853 (2003).
  Medline CASGoogle Scholar
• 39 Lotrich FE, Pollock BG. Aging and clinical pharmacology: implications for antidepressants. J. Clin. Pharmacol. 45, 1106–1122 (2005).
  Medline CASGoogle Scholar
• 40 Doogue MP, Polasek TM. Drug dosing in renal disease. Clin. Biochem. Rev. 32, 69–73 (2011).
  MedlineGoogle Scholar
• 41 Boyce RD, Handler SM, Karp JF, Hanlon JT. Age-related changes in antidepressant pharmacokinetics and potential drug–drug interactions: a comparison of evidence-based literature and package insert information. Am. J. Geriatr. Pharmacother. 10, 139–150 (2012).
  Medline CASGoogle Scholar
• 42 Bowie MW, Slattum PW. Pharmacodynamics in older adults: a review. Am. J. Geriatr. Pharmacother. 5, 263–303 (2007).
  Medline CASGoogle Scholar
• 43 Ballard C, Howard R. Neuroleptic drugs in dementia: benefits and harm. Nat. Rev. Neurosci. 7, 492–500 (2006).
  Medline CASGoogle Scholar
• 44 Pitychoutis PM, Kokras N, Sanoudou D, Dalla C, Papadopoulou-Daifoti Z. Pharmacogenetic considerations for late life depression therapy. Expert Opin. Drug Metab. Toxicol. 9, 989–999 (2013).
  Medline CASGoogle Scholar
• 45 Gerretsen P, Pollock BG. Pharmacogenetics and the serotonin transporter in late-life depression. Expert Opin. Drug Metab. Toxicol. 4, 1465–1478 (2008).
  Medline CASGoogle Scholar
• 46 Zhu J, Klein-Fedyshin M, Stevenson JM. Serotonin transporter gene polymorphisms and selective serotonin reuptake inhibitor tolerability: review of pharmacogenetic evidence. Pharmacotherapy 37, 1089–1104 (2017).
  MedlineGoogle Scholar
• 47 Heils A, Teufel A, Petri S et al. Allelic variation of human serotonin transporter gene expression. J. Neurochem. 66, 2621–2624 (1996).
  Medline CASGoogle Scholar
• 48 Collier DA, Stöber G, Li T et al. A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. Mol. Psychiatry 1, 453–460 (1996).
  Medline CASGoogle Scholar
• 49 Pollock BG, Ferrell RE, Mulsant BH et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 23, 587–590 (2000).
  Medline CASGoogle Scholar
• 50 Lotrich FE, Pollock BG, Kirshner M, Ferrell RF, Reynolds CF III. Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients. J. Psychiatry Neurosci. 33, 123–130 (2008).
  MedlineGoogle Scholar
• 51 Murphy GM, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch. Gen. Psychiatry 61, 1163–1169 (2004).
  Medline CASGoogle Scholar
• 52 Durham LK, Webb S, Milos P, Clary C, Seymour A. The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl.) 174, 525–529 (2004).
  Medline CASGoogle Scholar
• 53 Garfield LD, Dixon D, Nowotny P et al. Common selective serotonin reuptake inhibitor side effects in older adults associated with genetic polymorphisms in the serotonin transporter and receptors: data from a randomized controlled trial. Am. J. Geriatr. Psychiatry 22, 971–979 (2014).
  MedlineGoogle Scholar
• 54 Porcelli S, Fabbri C, Serretti A. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur. Neuropsychopharmacol. 22, 239–258 (2012).
  Medline CASGoogle Scholar
• 55 Mulsant BH, Pollock BG, Nebes R et al. A twelve-week, double-blind, randomized comparison of nortriptyline and paroxetine in older depressed inpatients and outpatients. Am. J. Geriatr. Psychiatry 9, 406–414 (2001).
  Medline CASGoogle Scholar
• 56 Reynolds CF, Dew MA, Pollock BG et al. Maintenance treatment of major depression in old age. N. Engl. J. Med. 354, 1130–1138 (2006).
  Medline CASGoogle Scholar
• 57 Marshe VS, Maciukiewicz M, Rej S et al. Norepinephrine transporter gene variants and remission from depression with venlafaxine treatment in older adults. Am. J. Psychiatry 174, 468–475 (2017).
  MedlineGoogle Scholar
• 58 Berm E, Kok R, Hak E, Wilffert B. Relation between CYP2D6 genotype, phenotype and therapeutic drug concentrations among nortriptyline and venlafaxine users in old age psychiatry. Pharmacopsychiatry 49, 186–190 (2016a).
  Medline CASGoogle Scholar
• 59 Eyre HA, Eskin A, Nelson SF et al. Genomic predictors of remission to antidepressant treatment in geriatric depression using genome-wide expression analyses: a pilot study. Int. J. Geriatr. Psychiatry 31, 510–517 (2016a).
  MedlineGoogle Scholar
• 60 Singh AB, Bousman CA, Ng CH, Byron K, Berk M. Effects of persisting emotional impact from child abuse and norepinephrine transporter genetic variation on antidepressant efficacy in major depression: a pilot study. Clin. Psychopharmacol. Neurosci. 13, 53–61 (2015).
  Medline CASGoogle Scholar
• 61 Preskorn SH, Kane CP, Lobello K et al. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine. J. Clin. Psychiatry 74, 614–621 (2013).
  Medline CASGoogle Scholar
• 62 Lavretsky H, Siddarth P, Kumar A, Reynolds CF. The effects of the dopamine and serotonin transporter polymorphisms on clinical features and treatment response in geriatric depression: a pilot study. Int. J. Geriatr. Psychiatry 23, 55–59 (2008).
  MedlineGoogle Scholar
• 63 Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the pharmacogenomics research network. Clin. Pharmacol. Ther. 89, 464–467 (2011).
  Medline CASGoogle Scholar
• 64 Hicks JK, Swen JJ, Thorn CF et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin. Pharmacol. Ther. 93, 402–408 (2013).
  Medline CASGoogle Scholar
• 65 Hicks JK, Bishop JR, Sangkuhl K et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin. Pharmacol. Ther. 98, 127–134 (2015).
  Medline CASGoogle Scholar
• 66 Hicks JK, Sangkuhl K, Swen JJ et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin. Pharmacol. Ther. 102(1), 37–44 (2017).
  Medline CASGoogle Scholar
• 67 Swen J, Wilting I, de Goede A et al. Pharmacogenetics: from bench to byte. Clin. Pharmacol. Ther. 83, 781–787 (2008).
  Medline CASGoogle Scholar
• 68 Bousman CA, Forbes M, Jayaram M et al. Antidepressant prescribing in the precision medicine era: a prescriber's primer on pharmacogenetic tools. BMC Psychiatry 17, 60 (2017).
  MedlineGoogle Scholar
• 69 Dodd S, Berk M. Predictors of antidepressant response: a selective review. Int. J. Psychiatry. Clin. Pract. 8, 91–100 (2004).
  Medline CASGoogle Scholar
• 70 Peterson K, Dieperink E, Ferguson L, Anderson J, Helfand M. Evidence brief: the comparative effectiveness, harms, and cost-effectiveness of antidepressant treatment versus usual care for major depressive disorder. VA Evidence-based Synthesis Program Evidence Briefs [Internet]. Department of Veteran Affairs (US), Washington, DC, USA (2016).
  Google Scholar
• 71 Amare AT, Schubert KO, Baune BT. Pharmacogenomics in the treatment of mood disorders: strategies and opportunities for personalized psychiatry. EPMA J. 8, 211–227 (2017).
  MedlineGoogle Scholar
• 72 Winner JG, Carhart JM, Altar CA, Allen JD, Dechairo BM. A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. Discov. Med. 16, 219–227 (2013).
  MedlineGoogle Scholar
• 73 Singh AB. Improved antidepressant remission in major depression via a pharmacokinetic pathway polygene pharmacogenetic report. Clin. Psychopharmacol. Neurosci. 13, 150–156 (2015).
  MedlineGoogle Scholar
• 74 Pérez V, Salavert A, Espadaler J et al. Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial. BMC Psychiatry 17(1), 250 (2017).
  MedlineGoogle Scholar
• 75 Bradley P, Shiekh M, Mehra V et al. Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: a randomized clinical trial demonstrating clinical utility. J. Psychiatr. Res. 96, 100–107 (2018).
  MedlineGoogle Scholar
• 76 Mayhew M, Jablonski M, Li J, Dechairo B. Combinatorial pharmacogenomics reduces polypharmacy and medication cost in elderly patients with anxiety and depression. Am. J. Geriatr. Psychiatry 25, S143–S144 (2017).
  Google Scholar
• 77 Berm EJJ, Gout-Zwart JJ, Luttjeboer J, Wilffert B, Postma MJ. A model based cost-effectiveness analysis of routine genotyping for CYP2D6 among older, depressed inpatients starting nortriptyline pharmacotherapy. PLoS ONE 11, 1–16 (2016b).
  Google Scholar
• 78 Berm EJJ, Hak E, Postma M et al. Effects and cost–effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial). Trials 16, 0–7 (2015).
  CASGoogle Scholar
• 79 Riecher-Rössler A. Sex and gender differences in mental disorders. Lancet Psychiatry 4, 8–9 (2017).
  MedlineGoogle Scholar
• 80 Jann MW, Cohen LJ. The influence of ethnicity and antidepressant pharmacogenetics in the treatment of depression. Drug Metabol. Drug Interact. 16, 39–67 (2000).
  Medline CASGoogle Scholar
• 81 United States Census Bureau. Centenarians: 2010. 2010 Census Spec Reports. (2012). https://www.census.gov/prod/cen2010/reports/c2010sr-03.pdf.
  Google Scholar